A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus

David R. Owens MD1 | Louis Monnier MD2 | Markolf Hanefeld MD3

1Diabetes Research Group, Institute of Life Sciences College of Medicine, Swansea University, Swansea, UK
2Laboratory of Human Nutrition and Atherosclerosis, Institute of Clinical Research, University of Montpellier, Montpellier, France
3Study Centre "Professor Hanefeld", GWT-Technical University Dresden, Dresden, Germany

Correspondence
Professor David R. Owens CBE, MD, FRCP, Diabetes Research Group, Institute of Life Sciences College of Medicine, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
Email: owensdr@cf.ac.uk

Funding information
Editorial assistance was funded by Sanofi.

Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular (CV) comorbidities, with CV disease being the most common cause of death in adults with T2DM. Although glucocentric therapies may improve glycaemic control (as determined by glycated haemoglobin levels), evidence suggests that this approach alone has limited beneficial effects on CV outcomes relative to improvements in lipid and blood pressure control. This may be explained in part by the fact that current antidiabetic treatment regimens primarily address overall glycaemia and/or fasting plasma glucose, but not the postprandial plasma glucose (PPG) excursions that have a fundamental causative role in increasing CV risk. This literature review evaluates the relationship between PPG and the risk of CV disease, discusses the treatment of T2DM with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and examines the associated CV outcomes. The literature analysis suggests that exaggerated PPG excursions are a risk factor for CV disease because of their adverse pathophysiologic effects on the vasculature, resulting in increased all-cause and CV-related mortality. Although GLP-1 RAs are well established in the current T2DM treatment paradigm, a subgroup of these compounds has a particularly pronounced, persistent and short-lived effect on gastric emptying and, hence, lower PPG substantially. However, current long-term data on CV outcomes with GLP-1 RAs are contradictory, with both beneficial and adverse effects having been reported. This review explores the opportunity to direct treatment towards controlling PPG excursions, thereby improving not only overall glycaemic control but also CV outcomes.

KEYWORDS
cardiovascular disease, diabetes complications, GLP-1 analogue, glycaemic control macrovascular disease, type 2 diabetes

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular (CV) disease, with adults with T2DM being 2 to 4 times more likely to succumb to CV disease or a cerebrovascular event (stroke or a transient ischaemic episode) than individuals with normal glucose tolerance.1,2 CV disease remains the most common cause of death among adults with T2DM,2 and the concurrence of CV disease in patients with T2DM results in a poorer prognosis compared with individuals with CV disease alone.2 Hence, a better understanding of the pathophysiology of vascular changes that underlie this relationship, and how best to address them, is likely to improve outcomes.

Several large studies have evaluated the relationship between glycaemic control with different treatment regimens and CV disease
in individuals with T2DM. The 10-year follow-up to the United Kingdom Prospective Diabetes Study (UKPDS) found that intensive treatment of T2DM with sulphonylurea, insulin or metformin lowered the patient’s risk of myocardial infarction (MI) as well as the risks of diabetes-related death and all-cause mortality vs conventional therapy (dietary restrictions).\(^5\)\(^-\)\(^10\) However, a meta-analysis of data from the UKPDS, combined with those of 3 other large randomized studies,\(^11\) found an overall 9% reduction in the risk of major CV events, mostly resulting from a 15% reduction in MI risk, for more- vs less-intensive glucose-control treatment regimens. Furthermore, there was a trend towards reduction in CV disease in individuals without previously reported CV events. Another systematic review of these same studies found that intensive vs conventional glucose control reduced the risk of certain CV outcomes, largely non-fatal MI, but not the risk of CV death or all-cause mortality.\(^12\) Similarly, a separate meta-analysis of data from these same 4 studies and another showed that intensive vs standard glycemic control significantly reduced coronary events, but again, with no significant effect on all-cause mortality. Of note, although these analyses demonstrated that intensive glucose therapy and the resulting improved glycemic control may reduce the risk of CV disease, hyperglycaemia is a weaker risk factor for CV disease than cholesterol or blood pressure. Hence, the relative impact of reducing hyperglycaemia on CV outcomes is less than the adequate control of these other concurrent risk factors.\(^13\)

Nevertheless, many studies have implied that postprandial plasma glucose (PPG) is a powerful and independent risk factor for CV disease.\(^14\) with the development of atherosclerosis having been described much earlier as a postprandial phenomenon.\(^15\) Glycaemic control is assessed predominantly using 3 measurements: primarily glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG), and rarely PPG. Considering that most individuals spend the majority of the day in the postprandial and postabsorptive states (approximately 21 hours per day) rather than the fasting state (3 hours per day, at the end of the night),\(^16\) the predominance of the PPG state within the daily metabolic cycle makes it an important target for the improvement of overall glycemic control.

The current T2DM treatment paradigm comprises various drug classes and allows for individualization of therapy to control FPG and PPG based on patients’ needs, disease characteristics and preferences.\(^17\) As part of this paradigm, 1 class of injectable therapy is the glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Since approval of the first of these compounds in 2006, these agents have enabled further tailoring of treatment to control FPG and CV risk, and a reduction of CV events and slow T2DM progression. The present review aims to evaluate the relationship between PPG and CV risk, and discuss the effects of treatment with the GLP-1 RAs, which appear to reduce CV risk in individuals with T2DM. The sodium-glucose cotransporter-2 (SGLT-2) inhibitors, particularly empagliflozin, also appear to lower CV risk in patients with T2DM.\(^19\)\(^,\)\(^20\) In contrast, the dipeptidyl peptidase-4 (DPP-4) inhibitors\(^21\) and insulin therapy\(^22\) do not affect the risk of CV disease in this population. While the CV effects of all of these drug classes warrant detailed discussion, the present review will focus on the GLP-1 RAs.

## 2 | CELLULAR AND VASCULAR EFFECTS OF ELEVATED PPG LEVELS

In vitro studies have shown that frequent elevations in glucose levels result in detrimental effects at the cellular level. High glucose levels for 2 hours in isolated hearts, and in cultured endothelial cells, induced apoptosis and the formation of nitrotyrosine, a marker of oxidative stress that is common in a number of pathologic conditions.\(^23\)\(^,\)\(^24\) Some studies have also shown that intermittent or fluctuating exaggerated PPG (defined as rising above 7.8 mmol/L [140 mg/dL] and/or not returning to preprandial levels within 2–3 hours)\(^25\) may be worse than persistent hyperglycaemia.\(^26\) For example, oscillating high glucose levels when compared with stable hyperglycaemia generates more nitrotyrosine and adhesion molecules and induces inflammatory cytokines in vitro using cultured human endothelial cells.\(^26\) Fluctuating glucose levels also cause enhanced apoptosis in cultured endothelial cells\(^27\) and increased mitogenicity in cultured human tubulo-interstitial cells.\(^28\)

This impact of oscillating glucose concentrations at the cellular level translates to changes in vasculature and haemodynamic parameters. The degree of glycemic variability has been shown to be positively related to the levels of oxidative stress markers in patients with T2DM.\(^29\) Increased glycemic variability also results in endothelial dysfunction, with increased levels of nitrotyrosine in individuals with and without T2DM.\(^30\)\(^,\)\(^31\) reflecting findings from earlier in vitro studies.\(^23\)\(^,\)\(^24\)

In response to acute hyperglycaemia, gene expression relating to free radical scavenging (detoxification) is downregulated in human skeletal muscle and adipose tissue.\(^32\) A study of healthy male volunteers aimed to mimic the blood glycemic parameters of poorly controlled patients with T2DM, and demonstrated that acute hyperglycaemia released free radicals, altered baroreflex activity and increased blood pressure and heart rate.\(^33\) Considered together, these observations support the hypothesis that oxidative stress is a major pathophysiologic mechanism responsible for the development of CV disease in patients with T2DM.

In addition, acute hyperglycaemia in healthy volunteers results in activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),\(^34\) a protein complex involved in stress responses that is linked to cancer and inflammatory diseases. Several other studies involving individuals with diabetes have shown that hyperglycaemia can activate the transcription of NF-κB-regulated inflammatory genes.\(^35\)

In a cross-sectional study of 232 Japanese patients with T2DM, exaggerated PPG excursions were independently correlated with the presence of microangiopathy in the form of diabetic retinopathy and neuropathy.\(^36\) Moreover, development and progression of macrovacular disease and atherosclerosis and, indeed, the 2-hour PPG level,
have been found to be significant determinants of carotid intima-media thickness (CIMT, a measure of atherosclerosis) and shown to be more closely correlated with CIMT than FPG in patients with T2DM and in subjects with normal glucose tolerance. Exaggerated PPG excursions reportedly also decrease vasodilation, resulting in an increase in the sheer force on the vascular endothelium resulting from reduced blood flow and increased blood pressure.

3 | EXAGGERATED PPG: AN INDEPENDENT RISK FACTOR FOR CV DISEASE AND ALL-CAUSE AND CV-RELATED MORTALITY

Endothelial dysfunction, including reduced vasodilation, and increased oxidative stress predict CV events in patients with documented CV disease. Table 1 summarizes the findings of several observational studies that demonstrated the association between PPG and development of CV disease in non-diabetic subjects and patients with T2DM. Moreover, these studies indicated that a high PPG level is also an independent predictor of all-cause mortality and death resulting from CV disease. This finding appears to be consistent across both sexes and across multiple races.

### TABLE 1

Reported risk of CV events with PPG excursions in observational studies in either the general population or patients with T2DM

| General population studies | Study type | Study findings |
|----------------------------|------------|----------------|
| de Vegt et al. (1999)⁴⁰   | Hoorn study: an 8-year follow-up of a population-based cohort of more than 2300 older (50–75 years) subjects | All-cause and CV mortality were predicted by increased 2-h PPG |
| Balkau et al. (1998)⁴¹   | 20-year follow-up to the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study comprising >17 000 males | Men with higher 2-h PPG excursions had an increased risk of all-cause and CV mortality compared with individuals in lower percentiles of the 2-h PPG distribution |
| Lowe et al. (1997)⁴²     | Analysis of white (n = 11 554) and African-American (n = 666) men (35–64 years) in the Chicago Heart Association Detection Project in Industry Study | Relative risk of all-cause and CV mortality was increased in subjects with asymptomatic post-load hyperglycaemia compared with those with normal post-load glucose levels |
| Donahue et al. (1987)⁴³   | Honolulu Heart Program: 12-year study of more than 8000 men (45–70 years) of Japanese ancestry | Based on a subset of 6394 non-diabetic subjects, those with the most extreme PPG excursions 1 h after a 50 g glucose challenge had a significantly increased risk of fatal coronary disease compared with individuals with lower PPG excursions |
| Nakagami (2004)⁴⁴       | Analysis of 5 studies of a total of more than 6800 subjects of Japanese and Asian Indian origin | Elevated 2-h PPG increased the risk of all-cause and CV mortality |

| Patients with impaired glucose tolerance and T2DM | Study type | Study findings |
|-------------------------------------------------|------------|----------------|
| DECODE Study Group (1999)⁴⁵ | DECODE: a study of 13 prospective European cohort studies, including more than 18 000 men and 7300 women with impaired glucose tolerance | Subjects with greater 2-h PPG excursions had an increased risk of death compared with individuals with less extreme PPG excursions |
| Chiasson et al. (2002)⁴⁶ and (2003)⁴⁷ | STOP-NIDDM: a study of approximately 1400 subjects comparing acarbose vs placebo | Acarbose not only reduced the progression from impaired glucose tolerance to T2DM, but was also associated with a reduction in CV events |
| Coutinho et al. (1999)⁴⁸ | A meta-regression comprising almost 100 000 subjects | Increased 2-h PPG levels were associated with a greater risk of CV events in subjects with normal glucose tolerance and also in individuals with glucose values within the diabetic range |
| Hanefeld et al. (1996)⁴⁹   | Diabetes Intervention Study: a prospective study of approximately 1100 patients with T2DM | Multivariate analysis revealed that PPG was an independent risk factor for death in subjects with PPG >10 mmol/L 1 h after breakfast, having a 40% greater relative risk of MI than those with PPG ≤8 mmol/L |
| Cavalot et al. (2006)⁵⁰     | A 5-year follow-up study of 529 patients with T2DM | PPG, but not FPG, was found to be an independent risk factor for CV events, particularly in women |
| Jackson et al. (1992)⁵¹     | The Islington Diabetes Survey: a study of 223 patients with T2DM | 2-h PPG after an oral glucose tolerance test was a better predictor of CV disease (including angina, MI or ischaemia) than HbA1c |

Abbreviations: CV, cardiovascular; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MI, myocardial infarction; PPG, postprandial plasma glucose; T2DM, type 2 diabetes mellitus.
addresses mainly PPG control, caused regression of CIMT. Altogether, these and other data indicate that addressing PPG excursions may have a protective effect against CV disease. In support of this, postchallenge plasma glucose and spikes have been shown to be more strongly associated with CIMT than are FPG and HbA1c.

However, results of interventional studies that have attempted to control PPG utilizing different therapeutic strategies to improve CV outcomes have been inconsistent. On the 1 hand, 2 studies, the STOP-NIDDM trial and the MEta-analysis of Risk Improvement under Acarbose (MERIA) meta-analysis, showed that administration of acarbose to address PPG excursions in patients with T2DM and in subjects with impaired glucose tolerance significantly reduced the risk of CV events, including MI. Furthermore, a study of Japanese patients with T2DM revealed that thrice-daily bolus insulin resulted in significantly (P < .05) slower progression of diabetic microvascular complications compared with a basal insulin regimen.

On the other hand, the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study, a 5-year randomized, placebo-controlled trial of nateglinide, a drug belonging to the aforementioned meglitinides class, in subjects with impaired glucose tolerance and evident CV disease and/or the presence of CV risk factors, reported that active treatment did not reduce CV and diabetes risk. These results may be explained by the fact that in this trial nateglinide seems to have been inefficient and unable to improve glucose tolerance. The Hyperglycemia and its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) study investigated the use of basal or thrice-daily bolus insulin to control FPG or PPG, respectively, in patients with T2DM who had experienced an acute MI. As PPG excursions were improved in patients treated with prandial insulin compared with those receiving basal insulin only, and total glucose exposure was similarly improved in both arms, one would expect the incidence of CV events to have been lower in the prandial vs basal insulin group. However, the risk of CV events was not reduced in either treatment group and, as a result, the study was halted prematurely. A subsequent post hoc analysis of this study did show a beneficial effect of reducing PPG on CV risk in older individuals. A feasible explanation for the absence of difference between the 2 treatment groups in the original HEART2D study may be the fact that both groups were treated with insulin, as insulin itself exerts a powerful inhibitory effect on activation of oxidative stress.

### 5 THE ROLE OF GLP-1 RAS IN THE CONTROL OF PPG

In recent years, incretin-based therapies have been introduced in the management of T2DM. Two distinct drug classes are currently approved: GLP-1 RAs and DPP-4 inhibitors. GLP-1 RAs mimic the actions of, and are more resistant to, degradation than native GLP-1, while DPP-4 inhibitors work by inhibiting the degradation of native GLP-1. Members of both the incretin group of preparations have been extensively shown to improve glycaemic control. Based on the pharmacodynamic and pharmacokinetic differences between the GLP-1 RAs, they can be divided into 2 main groups according to their predominant impact on either PPG, i.e. prandial (short acting), or FPG, i.e. non-prandial (long acting). Currently, a total of 6 GLP-1 RAs has been approved for the treatment of T2DM: 2 prandial GLP-1 RAs (exenatide twice daily and lixisenatide once daily) and 4 long-acting preparations (liraglutide once daily, albiglutide once weekly, dulaglutide once weekly, exenatide long-acting release once daily). A summary of the differences between the 2 groups in terms of their mechanisms of action and their precise effects on glycaemic control is given in Table 2.

A recent head-to-head comparison assessed the effects on PPG and gastric emptying of 2 GLP-1 RAs, short-acting lixisenatide and long-acting liraglutide. As expected, based on previous reports that the predominant effect of lixisenatide is to delay gastric

**TABLE 2** Comparison of prandial (short-) vs long-acting GLP-1 RAs

| Parameters                  | Short-acting GLP-1 RAs | Long-acting GLP-1 RAs |
|-----------------------------|------------------------|-----------------------|
| Compounds                   | Exenatide              | Albiglutide           |
|                             | Lixisenatide           | Dulaglutide           |
|                             |                        | Exenatide LAR         |
|                             |                        | Liraglutide           |
| Half-life                   | 2–5 h                  | 12 h—several days    |
| Effects                     |                        |                       |
| Fasting blood glucose levels| Modest reduction       | Strong reduction      |
| Postprandial hyperglycaemia | Strong reduction       | Modest reduction      |
| Fasting insulin secretion   | Modest stimulation     | Strong stimulation    |
| Postprandial insulin secretion| Reduction             | Modest stimulation   |
| Glucagon secretion          | Reduction              | Reduction             |
| Gastric-emptying rate       | Deceleration           | No effect             |
| Blood pressure              | Reduction              | Reduction             |
| Heart rate                  | No effect or small increase (0–2 bpm) | Moderate increase (2–5 bpm) |
| Body weight reduction       | 1–5 kg                 | 2–5 kg                |
| Induction of nausea         | 20–50%, attenuates slowly (weeks—many months) | 20–40%, attenuates quickly (~4–8 weeks) |

Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonist; LAR, long-acting release.
emptying, leading to reduced glucose reabsorption and subsequent reductions in PPG. Lixisenatide achieved greater reductions than did liraglutide in both area under the curve PPG0030–0430, and gastric emptying (P < .001 for both, for lixisenatide vs liraglutide). Surprisingly, FPG was unchanged for both treatments. This study also evaluated 24-hour heart rate, and showed differences between the 2 short- and long-acting agents.

6 | ACCELERATED HEART RATE WITH GLP-1 RAS AND ASSOCIATED RISK

Current literature suggests that an increase in heart rate of 10 bpm leads to at least a 20% higher risk of cardiac death, and that this elevated CV risk is similar to that associated with a 10 mm Hg increase in systolic blood pressure. A large prospective cohort study has shown that an elevated resting heart rate (RHR) is a strong risk factor for the development of fatal MI; compared with a RHR of <60 bpm, a RHR of >90 bpm is associated with a 2- and 3-fold higher risk of CV death in men and women, respectively. Also, in a study involving patients with T2DM with a high RHR, there was a greater incidence or progression of nephropathy and retinopathy, and an increased risk of all-cause mortality, CV death and major CV outcomes.

As noted above, published data indicate that GLP-1 RAs can influence heart rate, although the extent of this increase varies among medications. A recent analysis assessing the impact of lixisenatide, exenatide, liraglutide, albiglutide, exenatide long-acting release and dulaglutide on heart rate showed that, in patients with T2DM, prandial GLP-1 RAs led to a modest and transient increase in mean 24-h heart rate, whereas the long-acting GLP-1 RAs caused a more profound increase. When patients with T2DM were further assessed using 24-hour ambulatory heart rate monitoring, 8 weeks of treatment with liraglutide (1.2 or 1.8 mg) resulted in a clinically significant increase in 24-hour mean heart rate of 9 bpm (P < .0001 vs baseline) compared with an increase of 3 bpm with lixisenatide 20 μg. Moreover, the increase in heart rate with liraglutide was predominantly at night, abolishing the normal circadian rhythm in heart rate, which is reduced overnight. In a manner similar to lixisenatide, exenatide twice daily resulted in an insignificant 2 bpm increase in 24-hour mean heart rate in a 12-week interventional study, and also maintained the natural circadian rhythm in heart rate. Hence, some evidence suggests that any potentially adverse increases in heart rate appear to be limited to the long-acting GLP-1 RAs. The precise mechanism by which these drugs affect heart rate is unknown, although a study employing a murine model found that the GLP-1 receptor is central in the control of heart rate.

7 | CV OUTCOMES WITH GLP-1 RAS

As detailed in Section 4 above, some studies demonstrate a link between high PPG levels and CV outcomes, and show that controlling PPG can have CV benefits, while other studies are contradictory. Should such an association be confirmed, it seems plausible that GLP-1 RAs may have CV benefits, especially the short-acting preparations. It has been suggested that lixisenatide may have potential cardio-protective effects as, in isolated murine hearts subjected to acute ischaemia and reperfusion, lixisenatide reduced infarct size and improved cardiac function. Furthermore, in the Phase III GetGoal clinical trial programme for lixisenatide, improvements in hypertension were also reported for some patients in the lixisenatide treatment arms. As hypertension is a strong risk factor for CV disease, lowering hypertension rates associated with hyperglycaemia in general, and elevated PPG in particular, may contribute indirectly to the reduction of overall CV risk by GLP-1 RAs.

Similarly, exenatide may also have CV benefits. In pigs treated with either exenatide or saline, exenatide reduced MI size and prevented deterioration of systolic and diastolic cardiac function (including systolic wall thickening and myocardial stiffness). Similarly, both native exendin-4 and an exenatide analogue have been shown to have direct beneficial effects on cardiac function in murine models, including preservation of myocardial performance and protection against cardiac remodelling, suggesting that GLP-1 RAs have cardio-protective effects. GLP-1 RAs have demonstrated their ability to preserve or improve myocardial function during recovery following acute myocardial ischaemia. Suggested mechanisms for this benefit include attenuation of adverse cardiac remodelling (interstitial fibrosis and cardiac hypertrophy) mediated via reduced oxidative stress-induced injury, improved metabolic, blood flow or neural transmission and/or reduced inflammatory and extracellular matrix response. Moreover, in patients with ST-segment elevation MI, adjunctive exenatide to primary coronary intervention was associated with reduction in infarct size and improvement in subclinical left ventricular function. Contrarily, the FLaCtuAion reduction with inSUlin and Glp-1 Added together (FLAT-SUGAR) trial, assessing glucose variability in a 26-week randomized comparison of basal insulin plus twice-daily exenatide vs basal-bolus insulin in patients with T2DM at high CV risk, did not show any CV benefits of exenatide. Although patients receiving basal insulin-exenatide treatment presented with reduced glucose variability, lower body weight and a reduction in the levels of alanine aminotransferase and serum amyloid, while also maintaining equivalent HbA1c levels compared with those receiving basal-bolus insulin treatment, there was no statistically significant improvement in other CV risk biomarkers. Surprisingly, levels of urinary 8-isopGF2α (a reliable biomarker of activation of oxidative stress) were improved markedly in the basal-bolus insulin treatment group. This unexpected result can be explained by the fact that patients in both treatment arms were treated with insulin, and that, as mentioned previously, exogeneous insulin exerts an inhibitory effect on oxidative stress. Of note, positive CV effects were observed in the recent DURATION-8 trial, which assessed the efficacy and safety of co-initiation of exenatide and the SGLT-2 inhibitor dapagliflozin vs exenatide or dapagliflozin alone in patients with T2DM inadequately controlled with metformin. The combination of exenatide and dapagliflozin significantly improved CV risk factors (e.g. reduction in systolic blood pressure) compared with either drug alone.
seen to reduce cardiac rupture and infarct size and to improve cardiac output. However, the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study showed that liraglutide treatment vs placebo was not associated with improved clinical stability following hospitalization in subjects with advanced heart failure and reduced left ventricular ejection fraction, both with and without diabetes.

Since 2008, regulatory agencies require that all therapies for diabetes are assessed in a CV outcomes trial (CVOT) to ensure CV safety in order to grant and sustain approval. Currently, several CVOTs are ongoing for already approved GLP-1 RAs, including Exenatide Study of Cardiovascular Event Lowering (EXSCEL) for exenatide long-acting release, Researching CV Events with a Weekly Incretin in Diabetes (REWIND) for dulaglutide, and HARMONY Outcomes for albiglutide, and are expected to be completed in 2018/2019 (Table 3). The recently completed SUSTAIN-6 CVOT for semaglutide, a GLP-1 analogue currently in development for treating T2DM, showed that the primary composite endpoint (first occurrence of CV death, non-fatal MI or non-fatal stroke) occurred in 6.6% of patients receiving semaglutide vs 8.9% in the placebo group (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.58, 0.95; P < .001 for non-inferiority).

The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial assessed CV outcomes in patients with T2DM and acute coronary syndrome who were being treated with lixisenatide and was completed in February 2015. A total of 6068 patients were randomized and followed for a median of 25 months. A primary endpoint event (first occurrence of death from CV causes, non-fatal MI, non-fatal stroke or hospitalization for unstable angina) occurred in 13.4% of patients receiving lixisenatide vs 13.2% in the placebo group (HR, 1.02; 95% CI, 0.89, 1.17). This showed that lixisenatide was non-inferior to placebo (P < .001) but was not superior (P = .81). There were no differences in the rates of hospitalizations for heart failure or rates of death between the lixisenatide and placebo groups. Overall, the study showed that the addition of once-daily lixisenatide to the antidiabetic treatment regimen did not significantly impact on the rate of major CV events or other related serious adverse events in patients with acute coronary syndrome. Therefore, noting the specifics of the patient population and the trial design, the results of ELIXA do not directly support the theory proposed elsewhere in this review regarding the potential to affect CV outcomes via control of PPG.

In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study, which was completed in December 2015, a total of 9340 individuals with T2DM were randomized to either liraglutide or placebo for 3.5 to 5 years (median follow-up, 3.8 years). The trial’s primary endpoint was the composite outcome of the first occurrence of either CV death, non-fatal MI or non-fatal stroke, and occurred in 13.0% vs 14.9% of patients, respectively (HR, 0.87; 95% CI, 0.78, 0.97; P < .001 for non-inferiority, P = .01 for superiority). Furthermore, fewer patients died from CV causes (4.7% vs 6.0%, respectively; HR, 0.78; 95% CI, 0.66, 0.93; P = .007) and any cause (8.2% vs 9.6%, respectively; HR, 0.85; 95% CI, 0.74, 0.97; P = .02). Moreover, the rates of non-fatal MI, non-fatal stroke and hospitalization for heart failure were also non-significantly lower for liraglutide vs placebo. These results show that liraglutide can lower the risk of major adverse CV events compared with placebo. However, when analysing subgroups of patients stratified according to other antidiabetic therapies administered alongside liraglutide, the reduction in CV events was shown to be significant only in those patients receiving a single oral antidiabetic drug (OAD). This observation could potentially indicate that the significant reduction observed in the overall population may result mainly from the improvement seen in this particular subgroup, and that the beneficial effect of liraglutide on CV risk is less robust when patients are also treated with insulin and/or more than one OAD alongside liraglutide.

Although both of these CVOTs for these 2 currently available GLP-1 RAs were broadly similar in terms of overall design, there are major differences between them. While in LEADER only patients who were within 180 days post-acute coronary event and, hence, at the highest risk of a further CV event, were eligible for enrolment, in LEADER, patients with a pre-existing CV condition or with high risk for CV disease were included, corresponding to a more chronic CV risk status. Furthermore, ELIXA had a shorter median follow-up of 2.1 years compared with 3.8 years in LEADER. Also, in ELIXA the primary composite endpoint comprised the first occurrence of 4 individual endpoints (death from CV causes, non-fatal MI, non-fatal stroke or hospitalization for unstable angina), while in LEADER only 3 endpoints were included (CV death, non-fatal MI or non-fatal stroke). Of note, other baseline characteristics, including T2DM duration (mean [standard deviation] of 9.3 [8.3] years and 12.7 [8.0] years for ELIXA and LEADER, respectively) and HbA1c (mean [standard deviation] of 7.7 [1.3]% and 8.7 [1.5]% for ELIXA and LEADER, respectively) were also distinct between the 2 studies. As all of these differences between the 2 studies may have impacted the overall results, comparisons between ELIXA and LEADER must be made with caution. Furthermore, differences between the mechanisms of action of the short- and long-acting GLP-1 RAs should also be taken into account. Whereas the short-acting agent lixisenatide acts primarily by acutely lowering postprandial glucose excursions, the longer-acting agent liraglutide predominantly reduces the fasting glucose. Thus, differences in daily glycaemic variability between these 2 GLP-1 RAs

---

**TABLE 3** Currently ongoing CVOTs for GLP-1 RAs

| Trial name (ClinicalTrials.gov Identifier) | Drug | Planned patient number | Expected completion date |
|------------------------------------------|------|------------------------|-------------------------|
| EXSCEL (NCT01144338)                     | Exenatide | 14 000                | April 2018              |
| ITCA 650 (NCT01455896)                   | Dulaglutide | 4000                | July 2018               |
| REWIND (NCT01394952)                     | Albiglutide | 9622                | July 2018               |
| HARMONY Outcomes (NCT02465515)          |        | 9400                  | May 2019                |

Abbreviations: CVOT, cardiovascular outcomes trial; GLP-1 RA, glucagon-like peptide-1 receptor agonist.
may possibly have contributed to the different CV outcomes observed in the ELIXA and LEADER studies. Similarly, although not focused upon here, as semaglutide is an investigational compound, any direct comparisons with SUSTAIN-6 CVOT should also be made with care.

Because of these recently published and ongoing CVOTs in diabetes, the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was established. During the first summit meeting in 2015, the group noted the importance of distinguishing between CVOTs with a primary focus on the CV safety of novel drugs vs those that truly aim to assess the potential reduction of CV events. Notably, the former trial type is characterized by a study design that includes high-risk patients with T2DM, such as those included in ELIXA, and similar glycaemic control between active and standard treatment groups. Additionally, the group discussed whether the results observed to date are transferrable to wider patient groups. In brief, in cases of neutrality such as ELIXA, results could be extrapolated to patients with T2DM and a lower CV risk; however, in the event of CV reductions, as in LEADER, results should not be translated beyond the study group examined.

While the clinical studies of CV outcomes in patients treated with GLP-1 RAs appear to demonstrate a cardioprotective effect of these drugs, the precise mechanism behind this effect remains elusive. Aside from the possible link between glucose elevation and control, other factors may be involved. As the GLP-1 receptor is expressed widely throughout the body, including in the myocardium, the cardioprotective effects on GLP-1 RAs may, in part, result from direct action in the heart and through indirect actions involving GLP-1 signalling in vascular cells and other peripheral tissues.

8 | CONCLUDING REMARKS

Our analysis of current literature suggests that poor glycaemic control, and especially excessive glycaemic excursions predominantly after meals (PPG), may increase the risk of CV disease in patients with T2DM and individuals with normal glucose tolerance. However, the relationship between postprandial glucose hyperglycaemia and CV outcomes is complex, with additional research needed to characterize this association further.

In order to achieve HbA1c targets in patients with T2DM, individualized treatment that controls both PPG and FPG may be the best option, with antidiabetic medications that control PPG being of particular interest because of the role of PPG excursions in the pathophysiology of CV disease. In order to maintain a patient-centred, individualized approach to treatment, the respective distribution of postprandial and basal therapies should be modulated according to each patient’s 24-hour glycaemic profile. While this procedure is usually recommended for choosing the optimum pre-meal time at which boluses of rapid-acting insulin should be injected during implementation of a basal-plus insulin regimen, we believe that it is useful for a similar system to be implemented for treatment regimens involving basal insulin plus a short-acting GLP-1 RA, such as lixisenatide.

As discussed, the approved GLP-1 RAs have varying effects; some specifically control PPG, while others target FPG (Table 2). Hence, the use of prandial GLP-1 RAs in combination with therapies that control FPG may provide benefits resulting from a greater likelihood of achieving HbA1c targets, even in advanced T2DM. ELIXA, a CVOT assessing lixisenatide, has shown that lixisenatide does not pose a CV risk, while data from LEADER suggest that liraglutide may have beneficial effects on the risk of CV events. The absence of a detectable lowering of CV risk in ELIXA appears to weaken the argument that CV benefits can be achieved through lowering PPG. However, in this study, lixisenatide was administered only before breakfast, and while the PPG-lowering effect may have persisted to other meals, as has been demonstrated previously, the predominant effect would have been after breakfast. This raises the question as to whether a CV benefit would be seen if a short-acting GLP-1 RA had been administered more than once daily. It is important to note that this is not a licensed regimen, but could be an interesting concept to explore in a clinical trial setting. While the completion of ongoing CVOTs will provide further insight concerning the risk/benefit of individualized treatment with GLP-1 analogues, a recent publication has suggested that, based on results from completed CVOTs, which have not demonstrated a CV risk for the various compounds assessed, there is a need to reassess the Food and Drug Administration’s requirement of a CVOT for every new antihyperglycaemic agent. The authors suggest that a more individualized approach may be justified.

In conclusion, exaggerated PPG excursions appear to have a fundamental causative role in the relationship between T2DM and increased CV risk. This finding presents an opportunity to direct treatment towards also controlling PPG excursions, to improve both glycaemic control and also CV outcomes.

ACKNOWLEDGEMENTS

Editorial assistance was provided by Jane Bryant PhD, and Christina Holleywood PhD, both of Caudex (Oxford, UK) and was funded by Sanofi.

Conflict of interest

D. R. O. received honoraria from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Takeda for lectures and involvement in an advisory capacity. L. M. has nothing to declare. M. H. has served on advisory panels for Bristol-Myers Squibb, GlaxoSmithKline, Sanofi and Takeda; and on speakers’ bureau for Bayer Health Care, Eli Lilly, GlaxoSmithKline, Roche, Sanofi and Takeda.

Author contributions

D. R. O. contributed to the design, writing and critical revision of the manuscript at all stages of development. L. M. contributed to critical revision of the manuscript. M. H. contributed to the design and writing of the manuscript. All authors provided final approval of the manuscript and are accountable for its accuracy and integrity.

ORCID

David R. Owens http://orcid.org/0000-0003-1002-1238
Markolf Hanefeld http://orcid.org/0000-0001-7323-1203
REFERENCES
1. Benjamin SM, Geiss LS, Pan L, Engelgau MM, Greenland KJ. Self-reported heart disease and stroke among adults with and without diabetes - United States, 1999 to 2001: a report of the Center for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2003;52:1065-1070.
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes [UKPDS 34]. Lancet. 1998;352:854-865.
5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
6. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617-622.
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
9. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
10. Heller SR. A summary of the ADVANCE Trial. Diabetes Care. 2009;32(suppl 2):S199-S204.
11. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-2298.
12. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765-1772.
13. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;53:2079-2085.
14. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54:1-7.
15. Zilverstein DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
16. Monnier L, Colette C. Target for glycermic control: concentrating on glucose. Diabetes Care. 2009;32(suppl 2):S199-S204.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
18. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-742.
19. Marso SP, Daniels GH, Brown-Pressman K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
20. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
21. Karagiannis T, Bekiari E, Boura P, Tsapas A. Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2016;7:36-38.
22. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
23. Ceriello A, Quagliaro L, D’Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002;51:1076-1082.
24. Quagliaro L, Piconi L, Assaloni R, Martelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H oxidase activation. Diabetes. 2003;52:2795-2804.
25. Davidson J. Should postprandial glucose be measured and treated to a particular target? Yes. Diabetes Care. 2003;26:1919-1921.
26. Piconi L, Quagliaro L, Da Ros R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost. 2004;2:1453-1459.
27. Risco A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924-E930.
28. Jones SC, Sanders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulo- interstitial cells. Diabetologia. 1999;42:1113-1119.
29. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687.
30. Ceriello A, Taboga C, Tomutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-1218.
31. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.
32. Meugnien E, Faraj M, Rome S, et al. Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes. 2007;56:992-999.
33. Marfella R, Varrizzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol. 1995;268:E1167-E1173.
34. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of cML and activation of ras, p42/p44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes. 2003;52:621-633.
35. Miao F, Gonzalez IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004;279:18091-18097.
36. Shiraiwa T, Kaneto H, Miyatsuuka T, et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochim Biophys Acta. 2005;1739:339-345.
37. Hanefeld M, Koehl C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med. 2000;17:835-840.
38. Shige H, Ishikawa T, Suzukawa M, et al. Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol. 1999;84:1272-1274, A9.
39. Heitzer T, Schlinzig T, Krohn K, Meierertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
40. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoon population: the Hoon Study. Diabetologia. 1999;42:926-931.
41. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
42. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997;20:163-169.
43. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
44. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385-394.

45. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354:617-621.

46. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.

47. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.

48. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metagression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.

49. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.

50. Cavallot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-819.

51. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract. 1992;17:111-123.

52. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurtzschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073-1078.

53. Guardado-Mendoza R, Priolletta A, Jimenez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci. 2013;9:936-943.

54. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging. 2000;17:411-425.

55. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-219.

56. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol. 2007;27:2456-2462.

57. Temelkova-Kurtzschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K. Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830-1834.

58. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-B29.

59. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463-1476.

60. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycaemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381-386.

61. Raz I, Ceriello A, Wilson PW, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycaemia. Diabetes Care. 2011;34:1511-1513.

62. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? Diabetes Care. 2011;34:1058-1059.

63. Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53:562-571.

64. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203-216.

65. Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263-1273.

66. Becker RH, Stech J, Steinraeser A, Golor G, Pellissier F. Lixisenatide reduces postprandial hyperglycemia via gastrostolic and insulinotopic effects. Diabetes Metab Res Rev. 2015;31:610-618.

67. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycaemia. Regul Pept. 2013;185:1-8.

68. Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. 2009;52:6-10.

69. Cooney MT, Vartiaienen E, Laatikainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010;159:612-619.

70. Hillis GS,Hata J, Woodward M, et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2012;1:e002832.

71. Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283-1290.

72. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16:6.

73. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.

74. Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmarks cardiomycocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3:507-517.

75. Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med. 2013;11:84.

76. Sanofi-Aventis. Lixymia® (lixisenatide) summary of product characteristics. 2013; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140010.pdf. Accessed March 2, 2017.

77. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischaemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.

78. DeNicola M, Du J, Wang Z, et al. Stimulation of glucagon-like peptide-1 receptor through exenin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307:E630-E643.

79. Robinson E, Cassidy RS, Tate M, et al. Exenin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol. 2015;110:20.

80. Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ. Exenin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol. 2016;111:1.

81. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol. 2010;9:32.

82. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788-1803.

83. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33:2252-2260.

84. FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin
versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973-981.

85. O’Brien KD, Hirsch IB, Riddle MC, Probstfield JL. Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 2016;39:973-981. Diabetes Care. 2016;39:e188.

86. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004-1016.

87. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975-983.

88. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500-508.

89. London: Committee for Medicinal Products for Human Use. European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed April 21, 2016.

90. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.

91. Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169:631-638.

92. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.

93. Marso SP, Poulter NR, Nissen SE, et al. Design of the lixivanatide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823-830.

94. Schnell O, Standl E, Catrinoiu D, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33.

95. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.

96. Ahren B, Vorohkobina N, Souhami E, Demil N, Ye J, Aronson R. Equal improvement in glycemia with lixisenatide given before breakfast or the main meal of the day. J Diabetes Complications. 2014;28:735-741.

97. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39:738-742.